Prolonged grief during and beyond the pandemic: factors associated with levels of grief in a four time-point longitudinal survey of people bereaved in the first year of the COVID-19 pandemic.


Journal

Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579

Informations de publication

Date de publication:
2023
Historique:
received: 03 05 2023
accepted: 16 08 2023
medline: 2 11 2023
pubmed: 5 10 2023
entrez: 5 10 2023
Statut: epublish

Résumé

The COVID-19 pandemic has been a devastating and enduring mass-bereavement event, with uniquely difficult sets of circumstances experienced by people bereaved at this time. However, little is known about the long-term consequences of these experiences, including the prevalence of Prolonged Grief Disorder (PGD) and other conditions in pandemic-bereaved populations. A longitudinal survey of people bereaved in the UK between 16 March 2020 and 2 January 2021, with data collected at baseline ( At baseline, 628 (88.6%) of participants were female, with a mean age of 49.5 (SD 12.9). 311 (43.8%) deaths were from confirmed/suspected COVID-19. Sample demographics were relatively stable across time points. 34.6% of participants met the cut-off for indicated PGD at c. 13 months bereaved and 28.6% at final follow-up. Social isolation and loneliness in early bereavement and lack of social support over time strongly contributed to higher levels of prolonged grief symptoms, while feeling well supported by healthcare professionals following the death was associated with reduced levels of prolonged grief symptoms. Characteristics of the deceased most strongly associated with lower levels of prolonged grief symptoms, were a more distant relationship (e.g., death of a grandparent), an expected death and death occurring in a care-home. Participant characteristics associated with higher levels of prolonged grief symptoms included low level of formal education and existence of medical conditions. Results suggest higher than expected levels of PGD compared with pre-pandemic times, with important implications for bereavement policy, provision and practice now (e.g., strengthening of social and specialist support) and in preparedness for future pandemics and mass-bereavement events (e.g., guidance on infection control measures and rapid support responses).

Sections du résumé

Background
The COVID-19 pandemic has been a devastating and enduring mass-bereavement event, with uniquely difficult sets of circumstances experienced by people bereaved at this time. However, little is known about the long-term consequences of these experiences, including the prevalence of Prolonged Grief Disorder (PGD) and other conditions in pandemic-bereaved populations.
Methods
A longitudinal survey of people bereaved in the UK between 16 March 2020 and 2 January 2021, with data collected at baseline (
Results
At baseline, 628 (88.6%) of participants were female, with a mean age of 49.5 (SD 12.9). 311 (43.8%) deaths were from confirmed/suspected COVID-19. Sample demographics were relatively stable across time points. 34.6% of participants met the cut-off for indicated PGD at c. 13 months bereaved and 28.6% at final follow-up. Social isolation and loneliness in early bereavement and lack of social support over time strongly contributed to higher levels of prolonged grief symptoms, while feeling well supported by healthcare professionals following the death was associated with reduced levels of prolonged grief symptoms. Characteristics of the deceased most strongly associated with lower levels of prolonged grief symptoms, were a more distant relationship (e.g., death of a grandparent), an expected death and death occurring in a care-home. Participant characteristics associated with higher levels of prolonged grief symptoms included low level of formal education and existence of medical conditions.
Conclusion
Results suggest higher than expected levels of PGD compared with pre-pandemic times, with important implications for bereavement policy, provision and practice now (e.g., strengthening of social and specialist support) and in preparedness for future pandemics and mass-bereavement events (e.g., guidance on infection control measures and rapid support responses).

Identifiants

pubmed: 37794891
doi: 10.3389/fpubh.2023.1215881
pmc: PMC10546414
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1215881

Informations de copyright

Copyright © 2023 Harrop, Medeiros Mirra, Goss, Longo, Byrne, Farnell, Seddon, Penny, Machin, Sivell and Selman.

Déclaration de conflit d'intérêts

AP declared a potential financial interest relating to lobbying by the Childhood Bereavement Network and National Bereavement Alliance for additional financial support for the bereavement sector. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Oncologist. 2021 Jul;26(7):e1273-e1284
pubmed: 34060705
Palliat Med. 2021 May;35(5):843-851
pubmed: 33784908
SSM Ment Health. 2023 Dec;3:100198
pubmed: 36844796
Palliat Med. 2022 Apr;36(4):717-729
pubmed: 35176927
Global Health. 2021 Feb 11;17(1):19
pubmed: 33573673
Soc Sci Med. 2019 Dec;242:112599
pubmed: 31644975
Aust N Z J Public Health. 2012 Feb;36(1):14-6
pubmed: 22313700
Front Psychiatry. 2021 Jan 26;12:638866
pubmed: 33574777
Qual Life Res. 2014 May;23(4):1211-20
pubmed: 24129670
Omega (Westport). 2022 Jun;85(2):345-383
pubmed: 32640878
Asia Pac J Public Health. 2020 Jul;32(5):285-286
pubmed: 32633555
Death Stud. 2019;43(6):351-364
pubmed: 30015568
J Pain Symptom Manage. 2020 Aug;60(2):e81-e86
pubmed: 32376262
Sociol Health Illn. 2014 Sep;36(7):1095-110
pubmed: 25040507
J Pain Symptom Manage. 2021 Jun;61(6):e1-e4
pubmed: 33662513
Eur Respir J. 2015 May;45(5):1341-52
pubmed: 25614168
Palliat Med. 2021 Sep;35(8):1480-1491
pubmed: 34053347
BMJ. 2002 Jun 29;324(7353):1551
pubmed: 12089091
Eur J Psychotraumatol. 2021 Jul 22;12(1):1947563
pubmed: 34367528
J Pain Symptom Manage. 2017 Jul;54(1):17-26.e1
pubmed: 28450216
Death Stud. 2022;46(6):1287-1296
pubmed: 35167429
BMJ Open. 2020 Nov 17;10(11):e043828
pubmed: 33203640
Soc Sci Med. 2019 Jul;232:460-469
pubmed: 31230666
Lancet. 1971 Feb 27;1(7696):405-12
pubmed: 4100731
J Pain Symptom Manage. 2001 Dec;22(6):1016-26
pubmed: 11738164
Clin Psychol Sci. 2020 May;8(3):464-476
pubmed: 32550046
Cancer Manag Res. 2021 Jul 29;13:5875-5887
pubmed: 34349561
Support Care Cancer. 2010 Oct;18(10):1321-7
pubmed: 19816716
Death Stud. 2022;46(6):1354-1363
pubmed: 33427100
J Aging Health. 2017 Dec;29(8):1288-1307
pubmed: 28720010
Omega (Westport). 2022 Dec 21;:302228221144925
pubmed: 36542774
Death Stud. 2010 Sep;34(8):673-98
pubmed: 24482845
PLoS Med. 2009 Aug;6(8):e1000121
pubmed: 19652695
BMC Palliat Care. 2022 Oct 10;21(1):177
pubmed: 36210432
Am J Public Health. 2008 Nov;98(11):2092-8
pubmed: 18511733
J Med Internet Res. 2004 Sep 29;6(3):e34
pubmed: 15471760
Death Stud. 2022;46(1):34-42
pubmed: 34019471
Eur J Psychotraumatol. 2022 May 09;13(1):2062998
pubmed: 35572390
J Affect Disord. 2017 Apr 01;212:138-149
pubmed: 28167398
Palliat Care Soc Pract. 2021 Sep 12;15:26323524211033873
pubmed: 34541536
Palliat Med. 2023 Apr;37(4):586-601
pubmed: 36337051
Int J Ment Health Addict. 2023;21(1):51-70
pubmed: 34248442
Death Stud. 2022;46(1):43-52
pubmed: 34514956
Front Psychiatry. 2020 Oct 26;11:565698
pubmed: 33192687
Palliat Med. 2021 Dec;35(10):1985-1997
pubmed: 34676792
Death Stud. 2022;46(2):425-433
pubmed: 32189580
J Soc Work End Life Palliat Care. 2020 Apr-Jun;16(2):151-174
pubmed: 32233740
Palliat Med. 2020 Oct;34(9):1165-1181
pubmed: 32736489
Palliat Med. 2016 Sep;30(8):730-44
pubmed: 26944532
Soc Psychiatry Psychiatr Epidemiol. 2023 Oct;58(10):1535-1547
pubmed: 37039844
Soc Sci Med. 2021 Sep;285:114275
pubmed: 34365069
Front Psychiatry. 2022 May 27;13:878818
pubmed: 35711586
J Health Soc Behav. 2010 Mar;51(1):1-15
pubmed: 20420291
J Affect Disord. 2021 Jan 1;278:54-56
pubmed: 32950843
PLoS One. 2015 Mar 26;10(3):e0121101
pubmed: 25811912
J Pain Symptom Manage. 2020 Dec;60(6):e1-e4
pubmed: 33065207
J Nerv Ment Dis. 2019 Nov;207(11):913-920
pubmed: 31503183
PLoS One. 2021 May 27;16(5):e0252324
pubmed: 34043716
Psychooncology. 2008 Jun;17(6):612-20
pubmed: 17992703
Palliat Med. 2022 Sep;36(8):1305-1312
pubmed: 35786109
Palliat Med. 2020 Jul;34(7):871-888
pubmed: 32419630
Palliat Care Soc Pract. 2022 Apr 19;16:26323524221092456
pubmed: 35462622
BMC Palliat Care. 2016 Nov 8;15(1):92
pubmed: 27825330
J Pain Symptom Manage. 2021 Apr;61(4):e1-e4
pubmed: 33476753
J Affect Disord. 2011 Jul;132(1-2):231-8
pubmed: 21397336
Psychol Bull. 1992 Jul;112(1):155-9
pubmed: 19565683
J Gerontol B Psychol Sci Soc Sci. 2014 Jan;69(1):53-62
pubmed: 24077660

Auteurs

Emily Harrop (E)

Division of Population Medicine, Marie Curie Research Centre, Cardiff University, Cardiff, United Kingdom.

Renata Medeiros Mirra (R)

School of Dentistry, Cardiff University, Cardiff, United Kingdom.

Silvia Goss (S)

Division of Population Medicine, Marie Curie Research Centre, Cardiff University, Cardiff, United Kingdom.

Mirella Longo (M)

Division of Population Medicine, Marie Curie Research Centre, Cardiff University, Cardiff, United Kingdom.

Anthony Byrne (A)

Division of Population Medicine, Marie Curie Research Centre, Cardiff University, Cardiff, United Kingdom.

Damian J J Farnell (DJJ)

School of Dentistry, Cardiff University, Cardiff, United Kingdom.

Kathy Seddon (K)

Division of Population Medicine, Marie Curie Research Centre, Cardiff University, Cardiff, United Kingdom.

Alison Penny (A)

National Bereavement Alliance, London, United Kingdom.

Linda Machin (L)

School of Medicine, Keele University, Keele, United Kingdom.

Stephanie Sivell (S)

Division of Population Medicine, Marie Curie Research Centre, Cardiff University, Cardiff, United Kingdom.

Lucy E Selman (LE)

Palliative and End of Life Care Research Group, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH